Adage Capital Partners
DRUG

Adage Capital Partners’s Bright Minds Biosciences DRUG Stock Holding History

Adage Capital Partners’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.5M Sell
335,000
-160,743
-32% -$12.6M 0.03% 451
2026
Q1 		$36.2M Buy
495,743
+100,000
+25% +$8.05M 0.06% 320
2025
Q4 		$30.9M Hold
395,743
– – 0.05% 359
2025
Q3 		$24M Buy
395,743
+195,743
+98% +$7.6M 0.04% 415
2025
Q2 		$5.22M Hold
200,000
– – 0.01% 701
2025
Q1 		$7.21M Buy
200,000
+67,500
+51% +$2.47M 0.01% 644
2024
Q4 		$4.77M Buy
+132,500
New +$4.66M 0.01% 722

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Adage Capital Partners's DRUG Position: Q2 2026 in Review

Adage Capital Partners reduced its Bright Minds Biosciences (DRUG) stake by 32% in Q2 2026, selling an estimated $12.6M and leaving 335,000 shares worth $23.5M. The position accounts for 0.03% of the portfolio, ranked #451.

Adage Capital Partners first reported a position in DRUG in Q4 2024 and has held it in 7 quarters since. The position peaked at $36.2M in Q1 2026. 99 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Adage Capital Partners held 335,000 shares of Bright Minds Biosciences worth $23.5M as of Q2 2026.
  • Adage Capital Partners sold 160,743 Bright Minds Biosciences shares in Q2 2026, an estimated $12.6M.
  • Bright Minds Biosciences made up 0.03% of Adage Capital Partners's portfolio in Q2 2026, its #451 holding.
  • Adage Capital Partners first reported a position in Bright Minds Biosciences in Q4 2024 and has held it in 7 quarters since.
  • Adage Capital Partners's Bright Minds Biosciences position peaked at $36.2M in Q1 2026.
  • 99 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.